SCHEMBL211346

SCHEMBL211346

CC(C)(C)OC(=O)N[C@@H]1CN(S(=O)(=O)c2ccccc2)CC[C@@H]1NC(=O)C(=O)Nc1ccc(Cl)cn1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 1/20 0.42
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.41
RAB9A P51151 4/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NAMPT P43490 1/20 0.41
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
F13A1 P00488 1/20 0.38
TGM2 P21980 1/20 0.38
TGM1 P22735 1/20 0.38
RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209841 0.89 MAPK1 (0.40) LMNAGAAPOLBMEN1KMT2A
SCHEMBL210582 0.87 MAPK1 (0.39) LMNAGAAPOLBMEN1KMT2A
SCHEMBL207930 0.87 F10 (0.40) LMNAGAAPOLBMEN1KMT2A
SCHEMBL208895 0.84 F10 (0.43) TSHRSMN1; SMN2
SCHEMBL209455 0.84 CCNK (0.42) LMNAGAAPOLBMEN1KMT2A
SCHEMBL207795 0.83 NPC1 (0.39) LMNAGAATDP1TSHRRAB9A
SCHEMBL209285 0.82 F10 (0.39) LMNATSHRRAB9AALDH1A1NPC1
SCHEMBL210778 0.82 IDO1 (0.42) TDP1TSHRRAB9AMAPK1NPC1
SCHEMBL206636 0.81 IDO1 (0.41) ALDH1A1SMN1; SMN2
SCHEMBL4268193 0.81 SMN1; SMN2 (0.45) TDP1TSHRRAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090239857-A1 TRIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-24 US disclosed
EP-1864982-A1 TRIAMINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239857-A1 TRIAMINE DERIVATIVE F2, F12, F3 LMNA 279/4885GAA 4233/4885TDP1 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.